PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.
PreciseBreast (PDxBR) is an AI-enabled clinical-grade digital test that combines demographic and pathology data (e.g., age, tumor size, anatomic stage, lymph node status) with H&E image features of early-stage invasive breast cancer (IBC) to predict recurrence risk within 6 years. Previously validated on a Mount Sinai cohort with Oncotype (ODX) results, PDxBR demonstrated superior risk discrimination compared to ODX. This study extends these findings to a cohort from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.
Click here to view full PDF >
